Sheares was seen as a leading candidate to take over the top job when Gilmartin retired.
Bradley Sheares, a 20-year Merck man who ran Merck's U.S. pharmaceutical sales business, was leaving.
Under former head RaymondGilmartinRaymond Gilmartin, Sheares had been widely seen as a contender to be Merck's next CEO.
Under former head Raymond Gilmartin , Sheares had been widely seen as a contender to be Merck's next CEO.
Under former chief executive Raymond Gilmartin , Sheares had been widely seen as a contender to be Merck's next CEO.
Sheares was a 20-year veteran of the drug giant who started as a research fellow and moved into product management and sales.
Both Wold-Olsen and Sheares were suddenly reporting to Loescher, not to Clark.
Anderson wrote that Sheares would be replaced by someone from inside Merck.
Timothy Anderson, an analyst at Prudential Equity Group, was the first to report the news of Sheares' departure in a note to investors this morning.
Bradley Sheares was president of U.S. Human Health at Merck and had been in charge of selling the company's blockbuster drugs in the United States.
Raymond Gilmartin, both Wold-Olsen and Sheares reported directly to the CEO.
Bradley Sheares was president of U.S. Human Health at Merck (nyse: MRK - news - people ) and had been in charge of selling the company's blockbuster drugs in the United States.
Meanwhile, the departure of Bradley Sheares , who ran the company's U.S. operations, is one sign of the changes being brought about by Chief Executive RichardClarkRichard Clark as he works to steer Merck through the Vioxx mess.
Meanwhile, the departure of Bradley Sheares , who ran the company's U.S. operations, is one sign of the changes being brought about by Chief Executive Richard Clark as he works to steer Merck through the Vioxx mess.
应用推荐